Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer

doi:10.19586/j.2095-2341.2025.0035

Current Biotechnology ›› 2025, Vol. 15 ›› Issue (5): 839-844.DOI: 10.19586/j.2095-2341.2025.0035

• Reviews • Previous Articles Next Articles

Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer

Junyu LI¹(), Runze WANG²^,³(), Ziyi ZHANG-HUANG¹, Chao XIA¹, Yang YI¹, Fei XIE¹(), Xide ZHU³()

^1.College of Chemistry and Life Science，Beijing University of Technology，Beijing 100124，China
^2.School of Clinical Medicine，Shandong Second Medical University，Shandong Weifang 261053，China
^3.Department of Neurosurgery，Linyi People's Hospital，Shandong Linyi 276000，China

Received:2025-03-15 Accepted:2025-05-09 Online:2025-09-25 Published:2025-11-11
Contact: Fei XIE,Xide ZHU

Abstract

Abstract:

Colorectal cancer is one of the most common malignancies worldwide， with persistently high incidence and mortality rates. Early screening and diagnosis are crucial for reducing colorectal cancer mortality. In recent years， studies have shown that alterations in the composition and function of gut microbiota are closely associated with the occurrence and development of colorectal cancer. This article reviewed the research progress of gut microbiota in early diagnosis and prognostic evaluation of colorectal cancer， explored the potential of gut microbiota as biomarkers， and discussed the impact of modulating gut microbiota on colorectal cancer treatment， aiming to provide new perspectives and methods for early screening， diagnosis， and treatment of colorectal cancer.

Key words: gut microbiota, colorectal cancer, early diagnosis, prognostic evaluation, biomarker

摘要：

结直肠癌是全球常见的恶性肿瘤之一，其发病率和死亡率均居高不下。早期筛查和诊断对于降低结直肠癌的死亡率至关重要。近年来，研究表明肠道菌群的组成和功能变化与结直肠癌的发生、发展密切相关。综述了肠道菌群在结直肠癌早期诊断和预后评估中的研究进展，探讨了肠道菌群作为生物标志物的潜力以及调节肠道菌群对结直肠癌治疗的潜在影响，旨在为结直肠癌的早期筛查、诊断和治疗提供新的思路和方法。

关键词: 肠道菌群, 结直肠癌, 早期诊断, 预后评估, 生物标志物

CLC Number:

Q933

Junyu LI, Runze WANG, Ziyi ZHANG-HUANG, Chao XIA, Yang YI, Fei XIE, Xide ZHU. Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer[J]. Current Biotechnology, 2025, 15(5): 839-844.

李峻宇, 王润泽, 张黄子怡, 夏超, 仪杨, 谢飞, 朱锡德. 肠道菌群在结直肠癌早期诊断和预后评估中的研究进展[J]. 生物技术进展, 2025, 15(5): 839-844.

References 44

[1]	SUNG H, FERLAY J, SIEGEL R L, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J. Clin., 2021, 71(3): 209-249.
[2]	LIU S C, ZHANG H. Early diagnostic strategies for colorectal cancer[J]. World J. Gastroenterol., 2024, 30(33): 3818-3822.
[3]	SIEGEL R L, WAGLE N S, CERCEK A, et al.. Colorectal cancer statistics, 2023[J]. CA A Cancer J. Clin., 2023, 73(3): 233-254.
[4]	WIRBEL J, PYL P T, KARTAL E, et al.. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer[J]. Nat. Med., 2019, 25(4): 679-689.
[5]	YACHIDA S, MIZUTANI S, SHIROMA H, et al.. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer[J]. Nat. Med., 2019, 25(6): 968-976.
[6]	LIU N N, JIAO N, TAN J C, et al.. Multi-Kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts[J]. Nat. Microbiol., 2022, 7(2): 238-250.
[7]	THOMAS A M, MANGHI P, ASNICAR F, et al.. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation[J]. Nat. Med., 2019, 25(4): 667-678.
[8]	XU C, FAN L, LIN Y, et al.. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization[J/OL]. Gut Microbes, 2021, 13(1): 1980347[2025-05-09]. .
[9]	COKER O O, LIU C, WU W K K, et al.. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers[J/OL]. Microbiome, 2022, 10(1): 35[2025-05-09]. .
[10]	LOPÈS A, BILLARD E, CASSE A H, et al.. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer[J]. Int. J. Cancer, 2020, 146(11): 3147-3159.
[11]	ULGER TOPRAK N, YAGCI A, GULLUOGLU B M, et al.. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer[J]. Clin. Microbiol. Infect., 2006, 12(8): 782-786.
[12]	CHANG C W, LEE H C, LI L H, et al.. Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-fluorouracil/oxaliplatin-induced toxicity in colorectal cancer[J/OL]. Int. J. Mol. Sci., 2020, 21(2): 386[2025-05-09]. .
[13]	WANG N, FANG J Y. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer[J]. Trends Microbiol., 2023, 31(2): 159-172.
[14]	YANG Y, WENG W, PENG J, et al.. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21[J]. Gastroenterology, 2017, 152(4): 851-866.
[15]	CAO Y, WANG Z, YAN Y, et al.. Enterotoxigenic bacteroidesfragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p [J]. Gastroenterology, 2021, 161(5): 1552-1566.
[16]	PLEGUEZUELOS-MANZANO C, PUSCHHOF J, ROSENDAHL H A, et al.. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli [J]. Nature, 2020, 580(7802): 269-273.
[17]	SALESSE L, LUCAS C, HOANG M H T, et al.. Colibactin-producing Escherichia coli induce the formation of invasive carcinomas in a chronic inflammation-associated mouse model[J/OL]. Cancers, 2021, 13(9): 2060[2025-05-09]. .
[18]	CHEN H, TONG T, LU S Y, et al.. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis[J]. Cell Metab., 2023, 35(4): 651-666.
[19]	GUR C, IBRAHIM Y, ISAACSON B, et al.. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J]. Immunity, 2015, 42(2): 344-355.
[20]	GUR C, MAALOUF N, SHHADEH A, et al.. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1[J/OL]. OncoImmunology, 2019, 8(6): e1581531[2025-05-09]. .
[21]	HU L, LIU Y, KONG X, et al.. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κB/S 100A9 cascade[J/OL]. Front. Immunol., 2021, 12: 658681[2025-05-09]. .
[22]	CHEN T, LI Q, WU J, et al.. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism[J]. Cancer Immunol. Immunother., 2018, 67(10): 1635-1646.
[23]	GEIS A L, HOUSSEAU F. Procarcinogenic regulatory T cells in microbial-induced colon cancer[J/OL]. Oncoimmunology, 2016, 5(4): e1118601[2025-05-09]. .
[24]	DZIUBAŃSKA-KUSIBAB P J, BERGER H, BATTISTINI F, et al.. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer[J]. Nat. Med., 2020, 26(7): 1063-1069.
[25]	JANS M, KOLATA M, BLANCKE G, et al.. Colibactin-driven colon cancer requires adhesin-mediated epithelial binding[J]. Nature, 2024, 635(8038): 472-480.
[26]	TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J/OL]. Med. Sci. 2018, 6(2): 31[2025-05-09]. .
[27]	JIANG S S, XIE Y L, XIAO X Y, et al.. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer[J]. Cell Host Microbe, 2023, 31(5): 781-797.
[28]	NOSHO K, SUKAWA Y, ADACHI Y, et al.. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer[J]. World J. Gastroenterol., 2016, 22(2): 557-566.
[29]	PARK H E, KIM J H, CHO N Y, et al.. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma[J]. Virchows Arch., 2017, 471(3): 329-336.
[30]	XIE Y, JIAO X, ZENG M, et al.. Clinical significance of Fusobacterium nucleatum and microsatellite instability in evaluating colorectal cancer prognosis[J]. Cancer Manag. Res., 2022, 14: 3021-3036.
[31]	AMITAY E L, KRILAVICIUTE A, BRENNER H. Systematic review: gut microbiota in fecal samples and detection of colorectal neoplasms[J]. Gut Microbes, 2018, 9(4): 293-307.
[32]	CONDE-PÉREZ K, AJA-MACAYA P, BUETAS E, et al.. The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis[J]. Mol. Oncol., 2024, 18(5): 1093-1122.
[33]	MIMA K, NISHIHARA R, QIAN Z R, et al.. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12): 1973-1980.
[34]	WU S, JRHEE K, ALBESIANO E, et al.. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses[J]. Nat. Med., 2009, 15(9): 1016-1022.
[35]	PNOUGAYRÈDE J, HOMBURG S, TAIEB F, et al.. Escherichia coli induces DNA double-strand breaks in eukaryotic cells[J]. Science, 2006, 313(5788): 848-851.
[36]	XU Y, ZHAO J, MA Y, et al.. The microbiome types of colorectal tissue are potentially associated with the prognosis of patients with colorectal cancer[J/OL]. Front. Microbiol., 2023, 14: 1100873[2025-05-09]. .
[37]	O'KEEFE S J D. Diet, microorganisms and their metabolites, and colon cancer[J]. Nat. Rev. Gastroenterol. Hepatol., 2016, 13(12): 691-706.
[38]	JONES B V, BEGLEY M, HILL C, et al.. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome[J]. Proc. Natl. Acad. Sci. USA, 2008, 105(36): 13580-13585.
[39]	CHEN G, REN Q, ZHONG Z, et al.. Exploring the gut microbiome's role in colorectal cancer: diagnostic and prognostic implications[J/OL]. Front. Immunol., 2024, 15: 1431747[2025-05-09]. .
[40]	WU Y, ZHUANG J, ZHOU J, et al.. Prediction model of colorectal cancer (CRC) lymph node metastasis based on intestinal bacteria[J]. Clin. Transl. Oncol., 2023, 25(6): 1661-1672.
[41]	LIANG Q, CHIU J, CHEN Y, et al.. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clin. Cancer Res., 2017, 23(8): 2061-2070.
[42]	BAXTER N T, RUFFIN M T, ROGERS M A M, et al.. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions[J/OL]. Genome Med., 2016, 8(1): 37[2025-05-09]. .
[43]	HUANG Z, HUANG X, HUANG Y, et al.. Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model[J/OL]. Microbiol. Spectr., 2024, 12(5): e0272023[2025-05-09]. .
[44]	MA M, ZHENG Z, LI J, et al.. Association between the gut microbiota, inflammatory factors, and colorectal cancer: evidence from Mendelian randomization analysis[J/OL]. Front. Microbiol., 2024, 15: 1309111[2025-05-09]. .

Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 44

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xiaocong GUO, Xiaoya XU, Ziling XU, Honglin LUO, Xiaoqian MAO, Yongcan GUO. Pathological Correlation Mechanism of MicroRNA in Alzheimer′s Disease and its Potential for Early Diagnosis [J]. Current Biotechnology, 2026, 16(1): 61-67.
[2]	Xiaoya LIU, Shuomin ZHANG, Peng ZHENG, Rui MA, Chaojun ZHANG. Role and Mechanisms of DBNDD1 in Colorectal Cancer Development [J]. Current Biotechnology, 2025, 15(4): 726-734.
[3]	Yan LUO, Qi HONG, Leyi LIANG, Shiyue YU, Qiongxia CHEN, Xiaofang HAN, Hongyan ZHEN. Construction and Expression of Lentiviral Vector for Overexpression of WIPI2 Gene [J]. Current Biotechnology, 2025, 15(1): 135-141.
[4]	Yeerkenbieke BUERLAN, Wenjia GUO, Xiaogang DONG. Advances on the Function of POSTN in Tumor Microenvironment [J]. Current Biotechnology, 2024, 14(2): 205-210.
[5]	Kehao CAO, Junli ZHU, Huashan HE, Weizhuo XU. Impact of the Fourth Modifications of Patent Laws on Biotechnology Patent Applications and Industry Development [J]. Current Biotechnology, 2023, 13(5): 663-670.
[6]	Haitao CAO, Jing ZHU, Yunpeng MA, Xinghua CUI. Application of Machine Learning in Phenotypic Prediction of Gut Microbiota [J]. Current Biotechnology, 2023, 13(5): 671-680.
[7]	Linlin DU, Fei XIE, Xuemei MA. Pro-oncogenic Function and Therapeutic Significance of SALL4 [J]. Current Biotechnology, 2023, 13(5): 704-711.
[8]	Yuemaierabola ANWAIER, Lili SUN, Yeerkenbieke BUERLAN, Wenjia GUO. Advances on the Role of Piezo1 in Cancer [J]. Current Biotechnology, 2023, 13(5): 712-717.
[9]	Guanqun LI, Chaojie LANG, Feng XIA. Study on Establishment and Validation of Prognostic Evaluation Model for Hepatocellular Carcinoma Based on Methylomics Database [J]. Current Biotechnology, 2023, 13(2): 282-290.
[10]	Xingshu ZHU, Junjie HUANG, Caiming WENG, Wangwu LIU, Yongyuan CHEN, Huiyan CHEN, Hu ZHAO, Yu WANG, Chengzhi LIN. Screening and Functional Enrichment Analysis of Key Hub Genes in Lynch Syndrome-associated Colorectal Cancer Based on Bioinformatics Analysis [J]. Current Biotechnology, 2023, 13(2): 291-297.
[11]	Min YU, Min WANG, Yanhuan WEI, Yiyi LIU. Analysis of Potential Key Molecular Biomarkers and Immune Infiltration Characteristics of SARS-CoV-2 Virus Infection [J]. Current Biotechnology, 2022, 12(5): 760-768.
[12]	Meng WANG, Yang YI, Mengting SUN, Zijia LIU, Xue JIANG, Chen MA, Yifei SONG, Fei XIE. Biomedical Research Progress of Hydrogen‍⁃‍rich Water and Hydrogen‍⁃rich Saline： Animal Experiment [J]. Current Biotechnology, 2022, 12(3): 332-343.
[13]	Jiawei YAO, Bo QIU. Research Progress of Body Fluid Markers of Osteoarthritis Synovial Lesions [J]. Current Biotechnology, 2022, 12(3): 373-378.
[14]	Lina WU, Xiaozhong PENG, Chongmei LU. Expression and Biological Function of Long Noncoding RNA ZFAS1 in Colorectal Cancer [J]. Current Biotechnology, 2022, 12(3): 427-435.
[15]	Jiaxin YONG, Quanfeng WEI, Shanghui LIU. Expression Profile Screening of lncRNA and ceRNA Network Construction in Gastric Cancer Based on TCGA and GEO Databases [J]. Current Biotechnology, 2022, 12(1): 149-157.